CRO partners with humanized model developer to advance liver disease research

By Melissa Fassbender contact

- Last updated on GMT

(Image: iStock/Georgejason)
(Image: iStock/Georgejason)

Related tags: Hepatitis b

Seventh Wave Laboratories and Yecuris Corporation have announced an exclusive collaboration through which the CRO will provide various services.

Seventh Wave Laboratories is a consulting-based contract research organization (CRO) located in Maryland Heights, Mo.

The company provides services for discovery and preclinical drug development, including PK/ADME, bioanalysis, toxicology and pathology services.

Through the recently announced partnership, the CRO will provide services related to hepatitis B virus and C virus pharmacology studies using the Yecuris liver humanized FRG KO model.

Seventh Wave will also provide toxicology, metabolism and other pharmacology services using models developed by Yecuris Corporation. 

Portland, OR-based Yecuris was founded in 2007 to commercialize the FRG KO mouse technology and has been validating viremic and gene expression models for more than a year with Seventh Wave.

"Both companies are committed to supporting the partnership as long as it makes sense for our clients. In our pre-launch period, we’ve successfully supported a number of client-sponsored studies, and we believe there is a long future ahead ​with this partnership​," Joe Flynn, Chief Commercial Officer at Seventh Wave, told Outsourcing-Pharma.com.

"Both Seventh Wave and Yecuris have invested significantly in R&D to develop and validate this model — we’re past the theoretical stage and have proven the concept internally and also with client-sponsored studies​," Flynn added. "We’ve also spent a great deal of time with prospective clients in the pre-launch period to really understand what they are looking for in terms of study design and key endpoints​."

Related news

Show more

Related products

show more

The Complexities of Ophthalmic Drug Development

The Complexities of Ophthalmic Drug Development

Altasciences | 04-Oct-2022 | Technical / White Paper

Ophthalmic drug development comes with a unique set of challenges that can be mitigated by working with an end-to-end solution provider with regulatory...

dPCR Case Study

dPCR Case Study

CellCarta | 08-Aug-2022 | Case Study

Streamline your adoptive cell therapy program with digital PCR. Our team has a unique expertise in digital and quantitative PCR to support you in ensuring...

Strategic Approach to Immunogenicity Assessment

Strategic Approach to Immunogenicity Assessment

Altasciences | 17-May-2022 | Technical / White Paper

In this issue of The Altascientist we provide a detailed overview on the different goals and challenges that are presented by the validation of immunogenicity...

Related suppliers

Follow us

Products

View more

Webinars